GlassScriptPhysician profile
Laxmi Shah
NPI 1124337647
$2,171.52
in general payments reported to CMS, 2019-2025
20 companies · $436 in 2025
The $436 reported for 2025 was less than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.77 · 2021: $342 · 2022: $313 · 2023: $392 · 2024: $613 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $550.35 | 2021-2025 | |
| Lundbeck LLC | $447.46 | 2023-2025 | Vyepti |
| Pfizer INC. | $158.42 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $143.81 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $130.13 | 2021 | |
| Impel Pharmaceuticals INC. | $102.13 | 2023 | Trudhesa |
| Axsome Therapeutics, INC. | $101.39 | 2025 | Symbravo |
| Sk Life Science, INC. | $98.27 | 2023 | Xcopri |
| Lilly USA, LLC | $92.08 | 2021-2025 | Emgality, Kisunla |
| Alexion Pharmaceuticals, INC. | $85.80 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.50 | 2023 | Lifevest |
| Supernus Pharmaceuticals, INC. | $45.40 | 2019 | |
| Strongbridge US INC. | $29.37 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $22.32 | 2025 | Austedo Xr |
| Alnylam Pharmaceuticals INC. | $20.24 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $19.14 | 2025 | Keveyis |
| Neuropace, INC. | $18.41 | 2024 | |
| Acadia Pharmaceuticals INC | $16.97 | 2024 | Nuplazid |
| Sumitomo Pharma America, INC. | $14.66 | 2023 | Aptiom |
| Otsuka America Pharmaceutical, INC. | $13.67 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laxmi Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.